Publications

Explore peer-reviewed research by Datar Cancer Genetics on cancer screening, diagnosis, therapy guidance, and monitoring solutions.

Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies

Published By: Datar Cancer Genetics

Published Year: 2023

Accurate prostate cancer detection based on enrichment and characterization of prostate cancer-specific circulating tumour cells

Published By: Datar Cancer Genetics

Published Year: 2023

Accurate screening for early-stage breast cancer by detection and profiling of circulating tumour cells

Published By: Datar Cancer Genetics

Published Year: 2022

Concordancy of immunocytochemistry profiling of circulating tumour cells with immunohistochemistry for analysis of therapeutically relevant biomarkers

Published By: Datar Cancer Genetics

Published Year: 2021

PR01.01. Evaluation of circulating tumour cells for non-invasively discerning lung primary from metastasis

Published By: Datar Cancer Genetics

Published Year: 2021

OFP01.05 Circulating ensembles of tumour-associated cells facilitate efficient triaging of asymptomatic individuals for low-dose computed tomography

Published By: Datar Cancer Genetics

Published Year: 2021

PS3-13: Non-invasive screening for breast cancer risk based on circulating ensembles of tumour-associated cells

Published By: Datar Cancer Genetics

Published Year: 2021

Hallmark circulating tumour-associated cell clusters signify 230 times higher one-year cancer risk

Published By: Datar Cancer Genetics

Published Year: 2021

Circulating microtumours: A functional hallmark for cancer detection and management

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating ensembles of tumour-associated cells in genitourinary cancers

Published By: Datar Cancer Genetics

Published Year: 2020

P4-01-05: Circulating ensembles of tumour-associated cells for detection of breast cancer

Published By: Datar Cancer Genetics

Published Year: 2020

A14 Circulating ensembles of tumour-associated cells are ubiquitous in lung cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating ensembles of tumour-associated cells in gastrointestinal cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating ensembles of tumour-associated cells: A redoubtable new systemic hallmark of cancer

Published By: Datar Cancer Genetics

Published Year: 2019

PD01.11 Artificial intelligence can detect lung cancer from high-resolution microscopic images of conditioned peripheral blood

Published By: Datar Cancer Genetics

Published Year: 2019

Circulating ensembles of tumour-associated cells are ubiquitous in breast, ovarian and cervical cancers and atypical in asymptomatic individuals

Published By: Datar Cancer Genetics

Published Year: 2019

P087 - Diagnostic non-invasive biopsy can substitute conventional tissue-dependent procedures in suspected cases of renal cell carcinoma

Published By: Datar Cancer Genetics

Published Year: 2019

Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies

Published By: Datar Cancer Genetics

Published Year: 2023

Accurate prostate cancer detection based on enrichment and characterisation of prostate cancer-specific circulating tumour cells

Published By: Datar Cancer Genetics

Published Year: 2023

Path-24. Accurate identification of glial malignancies from peripheral blood

Published By: Datar Cancer Genetics

Published Year: 2022

Concordancy of immunocytochemistry profiling of circulating tumour cells with immunohistochemistry for analysis of therapeutically relevant biomarkers

Published By: Datar Cancer Genetics

Published Year: 2021

Analytical and clinical validation of the EasyCheck360^® platform for diagnostic triaging of symptomatic cases suspected of colorectal cancer

Published By: Datar Cancer Genetics

Published Year: 2021

PS2-40: Analytical and clinical validation of the EasyCheck360^® platform for diagnostic triaging of symptomatic cases suspected of breast cancer

Published By: Datar Cancer Genetics

Published Year: 2021

PR01.01. Evaluation of circulating tumour cells for non-invasively discerning lung primary from metastasis

Published By: Datar Cancer Genetics

Published Year: 2021

OFP01.05 Circulating ensembles of tumour-associated cells facilitate efficient triaging of asymptomatic individuals for low-dose computed tomography

Published By: Datar Cancer Genetics

Published Year: 2021

P059 Analytical and clinical validation of the EasyCheck360^® platform for diagnostic triaging of symptomatic cases suspected of prostate cancer

Published By: Datar Cancer Genetics

Published Year: 2020

VP01-10 Mutational landscape and tumour mutation burden of indian NSCLC patients

Published By: Datar Cancer Genetics

Published Year: 2020

VP01-23 Non-invasive diagnostic triaging of suspected lung cancers based on immunocytochemistry profiling of circulating tumour cells

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating microtumours: A functional hallmark for cancer detection and management

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating ensembles of tumour-associated cells in genitourinary cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating ensembles of tumour-associated cells in gastrointestinal cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Encyclopaedic liquid biopsies for guideline-compliant diagnostic work-up in gastrointestinal cancers

Published By: Datar Cancer Genetics

Published Year: 2020

B17: An mRNA signature that accurately discerns gliomas from healthy individuals

Published By: Datar Cancer Genetics

Published Year: 2020

B15: Circulating tumour cells express tissue-specific antigens in multiple cancers

Published By: Datar Cancer Genetics

Published Year: 2020

B62: Wholesome non-invasive liquid biopsies for pharmacodiagnostic work-up in breast cancer

Published By: Datar Cancer Genetics

Published Year: 2020

B61: Encyclopaedic non-invasive liquid biopsies for differential diagnosis in prostate cancer

Published By: Datar Cancer Genetics

Published Year: 2020

B16: Non-invasive liquid biopsies for guideline-compliant diagnostic assessment in ovarian cancers

Published By: Datar Cancer Genetics

Published Year: 2020

A14 Circulating ensembles of tumour-associated cells are ubiquitous in lung cancers

Published By: Datar Cancer Genetics

Published Year: 2020

BIOM-35. Multi-analyte assay for non-invasive diagnosis of brain tumours

Published By: Datar Cancer Genetics

Published Year: 2020

P4-01-05: Circulating ensembles of tumour-associated cells for detection of breast cancer

Published By: Datar Cancer Genetics

Published Year: 2020

Evaluation of circulating tumour cell clusters for pan-cancer non-invasive diagnostic triaging

Published By: Datar Cancer Genetics

Published Year: 2020

PATH-64. Prospective, blinded plasma-based analysis for diagnosis of newly diagnosed glioma

Published By: Datar Cancer Genetics

Published Year: 2019

PATH-43. Diagnosis of gliomas using circulating glial cells

Published By: Datar Cancer Genetics

Published Year: 2019

P087 - Diagnostic non-invasive biopsy can substitute conventional tissue-dependent procedures in suspected cases of renal cell carcinoma

Published By: Datar Cancer Genetics

Published Year: 2019

Circulating ensembles of tumour-associated cells are ubiquitous in breast, ovarian and cervical cancers and atypical in asymptomatic individuals

Published By: Datar Cancer Genetics

Published Year: 2019

PD01.11 Artificial intelligence can detect lung cancer from high-resolution microscopic images of conditioned peripheral blood

Published By: Datar Cancer Genetics

Published Year: 2019

Circulating ensembles of tumour-associated cells: A redoubtable new systemic hallmark of cancer

Published By: Datar Cancer Genetics

Published Year: 2019

PATH-37. Liquid biopsy for identification of newly diagnosed glioma

Published By: Datar Cancer Genetics

Published Year: 2018

Pan-cancer analysis of tumour mutation burden and other key ICI biomarkers in the Indian cohort

Published By: Datar Cancer Genetics

Published Year: 2023

Liquid and tissue profiling of the somatic mutational landscape of non-small cell lung cancer from an Indian cohort

Published By: Datar Cancer Genetics

Published Year: 2023

Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort

Published By: Datar Cancer Genetics

Published Year: 2023

Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer

Published By: Datar Cancer Genetics

Published Year: 2023

Multi-analyte liquid biopsies for molecular pathway guided personalised treatment selection in advanced refractory cancers: A clinical utility pilot study

Published By: Datar Cancer Genetics

Published Year: 2022

Circulating tumour cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers

Published By: Datar Cancer Genetics

Published Year: 2022

PS4-36: Non-invasive evaluation of chemoresistance in breast cancers using circulating tumour-associated cells

Published By: Datar Cancer Genetics

Published Year: 2021

Response to pazopanib-based combination regimen in a case of FGFR3-amplified gastric adenocarcinoma

Published By: Datar Cancer Genetics

Published Year: 2021

Excellent response with alpelisib and bicalutamide for advanced salivary duct carcinoma with PIK3CA mutation and high androgen receptor expression-A case report

Published By: Datar Cancer Genetics

Published Year: 2021

Angiogenesis inhibitors in personalised combination regimens for the treatment of advanced refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2021

Improved treatment outcomes by using patient-specific drug combinations in mammalian target of rapamycin-activated advanced metastatic cancers

Published By: Datar Cancer Genetics

Published Year: 2021

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumours

Published By: Datar Cancer Genetics

Published Year: 2021

Re-establishing responsiveness in a case of refractory metastatic rectal cancer with a personalised de novo combination regimen

Published By: Datar Cancer Genetics

Published Year: 2021

Mutational landscape and tumour mutation burden of Indian NSCLC patients

Published By: Datar Cancer Genetics

Published Year: 2020

73P Anti-angiokinases in patient-specific combination regimens can improve outcomes in advanced metastatic cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Liquid biopsies to enable non-invasive real-time functional chemoresistance profiling in solid organ cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Multi-analyte liquid biopsies based treatment in advanced refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2020

CLO20-028 Clinical utility of encyclopaedic tumour analysis to treat breast cancer patients who have failed standard of care treatments

Published By: Datar Cancer Genetics

Published Year: 2020

Encyclopaedic tumour analysis-guided personalised treatments for advanced refractory breast cancer

Published By: Datar Cancer Genetics

Published Year: 2020

303 Poster - Real-time non-invasive chemoresistance profiling of circulating tumour-associated cells in breast cancers to determine resistance towards mitotic inhibitors

Published By: Datar Cancer Genetics

Published Year: 2020

302 Poster - Circulating tumour-associated cells in breast cancers are resistance educated towards prior anthracycline treatments

Published By: Datar Cancer Genetics

Published Year: 2020

Viable Circulating Ensembles of Tumour-Associated Cells Persist in Patients with No Radiologically Detectable Disease after Treatment in Head and Neck Cancer

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating Tumour-Associated Cells in Head and Neck Cancers are Resistance Educated per Previous Chemotherapy Treatments

Published By: Datar Cancer Genetics

Published Year: 2020

47P Improved treatment outcomes by using patient-specific drug combinations in mTOR-activated advanced metastatic cancers

Published By: Datar Cancer Genetics

Published Year: 2020

PD-L1 profiling of circulating tumour cells for immune checkpoint inhibitor therapy in head and neck cancers

Published By: Datar Cancer Genetics

Published Year: 2020

PD-L1 profiling of circulating tumour cells for immune checkpoint inhibitor therapy in gastroesophageal cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Effect of previous chemotherapy treatments on circulating tumour-associated cells in colorectal cancer

Published By: Datar Cancer Genetics

Published Year: 2020

A49: Viable circulating ensembles of tumour-associated cells persist in pretreated patients with solid organ cancers, showing no radiologically detectable disease

Published By: Datar Cancer Genetics

Published Year: 2020

B35 Circulating tumour-associated cells in lung cancers are resistance educated per previous chemotherapy treatments

Published By: Datar Cancer Genetics

Published Year: 2020

P4-01-17: Viable circulating ensembles of tumour-associated cells persist in patients with no radiologically detectable disease after treatment in breast cancer

Published By: Datar Cancer Genetics

Published Year: 2020

P6-10-11: In vitro chemo interrogation of viable circulating tumour-associated cells from breast cancer patients

Published By: Datar Cancer Genetics

Published Year: 2020

Encyclopaedic tumour analysis-guided treatments with conventional drugs outperform available alternatives in refractory head and neck cancers

Published By: Datar Cancer Genetics

Published Year: 2020

A case report of androgen receptor inhibitor therapy in recurrent high-grade serous ovarian cancer

Published By: Datar Cancer Genetics

Published Year: 2020

Liquid biopsy and multi-analyte testing-guided treatment of HER2-positive periampullary adenocarcinoma with durable complete response after trastuzumab-based therapy

Published By: Datar Cancer Genetics

Published Year: 2020

Long overall survival in a case of refractory stage IV squamous cell carcinoma of lung treated with personalised de novo combination regimen

Published By: Datar Cancer Genetics

Published Year: 2020

Clinical utility of circulating tumour-associated cells to predict and monitor chemo-response in solid tumours

Published By: Datar Cancer Genetics

Published Year: 2020

Multi-analyte interrogation-based treatment of advanced refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2020

11P - PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer

Published By: Datar Cancer Genetics

Published Year: 2019

371P - Clinical utility of encyclopaedic tumour analysis to treat patients with advanced refractory head and neck cancers

Published By: Datar Cancer Genetics

Published Year: 2019

INNV-26. In vitro chemoresistance profiles of circulating glial cells replicate chemo characteristics of tumour tissue

Published By: Datar Cancer Genetics

Published Year: 2019

CMET-37. Clinical utility of encyclopaedic tumour analysis to treat patients with brain metastasis in refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2019

102P - Encyclopaedic tumour analysis (ETA)-guided combination regimens of hormone receptor antagonists with other systemic agents for treatment of refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2019

45P - Circulating tumour-associated cells in oesophageal cancers are resistance educated per previous chemo treatments

Published By: Datar Cancer Genetics

Published Year: 2019

94P - Encyclopaedic tumour analysis-guided treatments with conventional drugs outperform available alternatives in refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2019

Tumour-infiltrating lymphocytes show in vitro cytotoxic activity against tumour cells in multiple cancers

Published By: Datar Cancer Genetics

Published Year: 2019

Clinical efficacy of combination therapies with androgen receptor antagonists for treatment of multiple refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2019

PD01.10 Diagnostic non-invasive biopsy can substitute conventional tissue-dependent procedures in suspected cases of lung cancer

Published By: Datar Cancer Genetics

Published Year: 2019

1934P - Encyclopaedic tumour analysis for organ-agnostic treatment with axitinib in combination regimens for advanced cancers

Published By: Datar Cancer Genetics

Published Year: 2019

1972P - In vitro functional interrogation of viable circulating tumour-associated cells (C-TACs) for evaluating platin resistance

Published By: Datar Cancer Genetics

Published Year: 2019

111P - mTOR inhibitors in combination regimens guided by encyclopaedic tumour analysis show superior outcomes compared to monotherapy in refractory cancers

Published By: Datar Cancer Genetics

Published Year: 2019

Adaptive, iterative and long-term personalised therapy management in a case of stage IV refractory NSCLC

Published By: Datar Cancer Genetics

Published Year: 2019

Encyclopaedic tumour analysis for guiding treatment of advanced, broadly refractory cancers: Results from the RESILIENT trial

Published By: Datar Cancer Genetics

Published Year: 2019

Liquid biopsy in periampullary carcinoma

Published By: Datar Cancer Genetics

Published Year: 2016

PS4-36: Non-invasive evaluation of chemoresistance in breast cancers using circulating tumour-associated cells

Published By: Datar Cancer Genetics

Published Year: 2021

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumours

Published By: Datar Cancer Genetics

Published Year: 2021

303 Poster - Real-time non-invasive chemoresistance profiling of circulating tumour-associated cells in breast cancers to determine resistance towards mitotic inhibitors

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating microtumours: A functional hallmark for cancer detection and management

Published By: Datar Cancer Genetics

Published Year: 2020

P6-10-11: In vitro chemo interrogation of viable circulating tumour-associated cells from breast cancer patients

Published By: Datar Cancer Genetics

Published Year: 2020

P4-01-17: Viable circulating ensembles of tumour-associated cells persist in patients with no radiologically detectable disease after treatment in breast cancer

Published By: Datar Cancer Genetics

Published Year: 2020

B35 Circulating tumour-associated cells in lung cancers are resistance educated per previous chemotherapy treatments

Published By: Datar Cancer Genetics

Published Year: 2020

A49: Viable circulating ensembles of tumour-associated cells persist in pretreated patients with solid organ cancers, showing no radiologically detectable disease

Published By: Datar Cancer Genetics

Published Year: 2020

PD-L1 profiling of circulating tumour cells for immune checkpoint inhibitor therapy in gastroesophageal cancers

Published By: Datar Cancer Genetics

Published Year: 2020

PD-L1 profiling of circulating tumour cells for immune checkpoint inhibitor therapy in head and neck cancers

Published By: Datar Cancer Genetics

Published Year: 2020

Circulating tumour-associated cells in head and neck cancers are resistance educated per previous chemotherapy treatments

Published By: Datar Cancer Genetics

Published Year: 2020

Viable circulating ensembles of tumour-associated cells persist in patients with no radiologically detectable disease after treatment in head and neck cancer

Published By: Datar Cancer Genetics

Published Year: 2020

302 Poster - Circulating tumour-associated cells in breast cancers are resistance educated towards prior anthracycline treatments

Published By: Datar Cancer Genetics

Published Year: 2020

Clinical utility of circulating tumour-associated cells to predict and monitor chemo-response in solid tumours

Published By: Datar Cancer Genetics

Published Year: 2020

Adaptive, iterative, and long-term personalised therapy management in a case of stage IV refractory NSCLC

Published By: Datar Cancer Genetics

Published Year: 2019

1972P - In vitro functional interrogation of viable circulating tumour-associated cells (C-TACs) for evaluating platin resistance

Published By: Datar Cancer Genetics

Published Year: 2019

11P - PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer

Published By: Datar Cancer Genetics

Published Year: 2019

PD01.10 Diagnostic non-invasive biopsy can substitute conventional tissue-dependent procedures in suspected cases of lung cancer

Published By: Datar Cancer Genetics

Published Year: 2019

45P - Circulating tumour-associated cells in oesophageal cancers are resistance educated per previous chemo treatments

Published By: Datar Cancer Genetics

Published Year: 2019

Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies

Accurate prostate cancer detection based on enrichment and characterization of prostate cancer-specific circulating tumour cells

Accurate screening for early-stage breast cancer by detection and profiling of circulating tumour cells

Concordancy of immunocytochemistry profiling of circulating tumour cells with immunohistochemistry for analysis of therapeutically relevant biomarkers

PR01.01. Evaluation of circulating tumour cells for non-invasively discerning lung primary from metastasis

OFP01.05 Circulating ensembles of tumour-associated cells facilitate efficient triaging of asymptomatic individuals for low-dose computed tomography

PS3-13: Non-invasive screening for breast cancer risk based on circulating ensembles of tumour-associated cells

Hallmark circulating tumour-associated cell clusters signify 230 times higher one-year cancer risk

Circulating microtumours: A functional hallmark for cancer detection and management

Circulating ensembles of tumour-associated cells in genitourinary cancers

P4-01-05: Circulating ensembles of tumour-associated cells for detection of breast cancer

A14 Circulating ensembles of tumour-associated cells are ubiquitous in lung cancers

Circulating ensembles of tumour-associated cells in gastrointestinal cancers

Circulating ensembles of tumour-associated cells: A redoubtable new systemic hallmark of cancer

PD01.11 Artificial intelligence can detect lung cancer from high-resolution microscopic images of conditioned peripheral blood

Circulating ensembles of tumour-associated cells are ubiquitous in breast, ovarian and cervical cancers and atypical in asymptomatic individuals

P087 - Diagnostic non-invasive biopsy can substitute conventional tissue-dependent procedures in suspected cases of renal cell carcinoma

Profiling of circulating glial cells for accurate blood-based diagnosis of glial malignancies

Accurate prostate cancer detection based on enrichment and characterisation of prostate cancer-specific circulating tumour cells

Path-24. Accurate identification of glial malignancies from peripheral blood

Concordancy of immunocytochemistry profiling of circulating tumour cells with immunohistochemistry for analysis of therapeutically relevant biomarkers

Analytical and clinical validation of the EasyCheck360® platform for diagnostic triaging of symptomatic cases suspected of colorectal cancer

PS2-40: Analytical and clinical validation of the EasyCheck360® platform for diagnostic triaging of symptomatic cases suspected of breast cancer

PR01.01. Evaluation of circulating tumour cells for non-invasively discerning lung primary from metastasis

OFP01.05 Circulating ensembles of tumour-associated cells facilitate efficient triaging of asymptomatic individuals for low-dose computed tomography

P059 Analytical and clinical validation of the EasyCheck360® platform for diagnostic triaging of symptomatic cases suspected of prostate cancer

VP01-10 Mutational landscape and tumour mutation burden of indian NSCLC patients

VP01-23 Non-invasive diagnostic triaging of suspected lung cancers based on immunocytochemistry profiling of circulating tumour cells

Circulating microtumours: A functional hallmark for cancer detection and management

Circulating ensembles of tumour-associated cells in genitourinary cancers

Circulating ensembles of tumour-associated cells in gastrointestinal cancers

Encyclopaedic liquid biopsies for guideline-compliant diagnostic work-up in gastrointestinal cancers

B17: An mRNA signature that accurately discerns gliomas from healthy individuals

B15: Circulating tumour cells express tissue-specific antigens in multiple cancers

B62: Wholesome non-invasive liquid biopsies for pharmacodiagnostic work-up in breast cancer

B61: Encyclopaedic non-invasive liquid biopsies for differential diagnosis in prostate cancer

B16: Non-invasive liquid biopsies for guideline-compliant diagnostic assessment in ovarian cancers

A14 Circulating ensembles of tumour-associated cells are ubiquitous in lung cancers

BIOM-35. Multi-analyte assay for non-invasive diagnosis of brain tumours

P4-01-05: Circulating ensembles of tumour-associated cells for detection of breast cancer

Evaluation of circulating tumour cell clusters for pan-cancer non-invasive diagnostic triaging

PATH-64. Prospective, blinded plasma-based analysis for diagnosis of newly diagnosed glioma

PATH-43. Diagnosis of gliomas using circulating glial cells

P087 - Diagnostic non-invasive biopsy can substitute conventional tissue-dependent procedures in suspected cases of renal cell carcinoma

Circulating ensembles of tumour-associated cells are ubiquitous in breast, ovarian and cervical cancers and atypical in asymptomatic individuals

PD01.11 Artificial intelligence can detect lung cancer from high-resolution microscopic images of conditioned peripheral blood

Circulating ensembles of tumour-associated cells: A redoubtable new systemic hallmark of cancer

PATH-37. Liquid biopsy for identification of newly diagnosed glioma

Pan-cancer analysis of tumour mutation burden and other key ICI biomarkers in the Indian cohort

Liquid and tissue profiling of the somatic mutational landscape of non-small cell lung cancer from an Indian cohort

Comprehensive molecular profiling from liquid and tissue for analysing the somatic mutational landscape in an Indian breast cancer cohort

Liquid and tissue profiling of targetable co-mutations with KRAS in non-small cell lung cancer

Multi-analyte liquid biopsies for molecular pathway guided personalised treatment selection in advanced refractory cancers: A clinical utility pilot study

Circulating tumour cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers

PS4-36: Non-invasive evaluation of chemoresistance in breast cancers using circulating tumour-associated cells

Response to pazopanib-based combination regimen in a case of FGFR3-amplified gastric adenocarcinoma

Excellent response with alpelisib and bicalutamide for advanced salivary duct carcinoma with PIK3CA mutation and high androgen receptor expression-A case report

Angiogenesis inhibitors in personalised combination regimens for the treatment of advanced refractory cancers

Improved treatment outcomes by using patient-specific drug combinations in mammalian target of rapamycin-activated advanced metastatic cancers

Development and validation of a multigene variant profiling assay to guide targeted and immuno therapy selection in solid tumours

Re-establishing responsiveness in a case of refractory metastatic rectal cancer with a personalised de novo combination regimen

Mutational landscape and tumour mutation burden of Indian NSCLC patients

73P Anti-angiokinases in patient-specific combination regimens can improve outcomes in advanced metastatic cancers

Liquid biopsies to enable non-invasive real-time functional chemoresistance profiling in solid organ cancers

Multi-analyte liquid biopsies based treatment in advanced refractory cancers

CLO20-028 Clinical utility of encyclopaedic tumour analysis to treat breast cancer patients who have failed standard of care treatments

Encyclopaedic tumour analysis-guided personalised treatments for advanced refractory breast cancer

303 Poster - Real-time non-invasive chemoresistance profiling of circulating tumour-associated cells in breast cancers to determine resistance towards mitotic inhibitors

302 Poster - Circulating tumour-associated cells in breast cancers are resistance educated towards prior anthracycline treatments

Viable Circulating Ensembles of Tumour-Associated Cells Persist in Patients with No Radiologically Detectable Disease after Treatment in Head and Neck Cancer

Circulating Tumour-Associated Cells in Head and Neck Cancers are Resistance Educated per Previous Chemotherapy Treatments

47P Improved treatment outcomes by using patient-specific drug combinations in mTOR-activated advanced metastatic cancers

PD-L1 profiling of circulating tumour cells for immune checkpoint inhibitor therapy in head and neck cancers

PD-L1 profiling of circulating tumour cells for immune checkpoint inhibitor therapy in gastroesophageal cancers

Effect of previous chemotherapy treatments on circulating tumour-associated cells in colorectal cancer

A49: Viable circulating ensembles of tumour-associated cells persist in pretreated patients with solid organ cancers, showing no radiologically detectable disease

B35 Circulating tumour-associated cells in lung cancers are resistance educated per previous chemotherapy treatments

P4-01-17: Viable circulating ensembles of tumour-associated cells persist in patients with no radiologically detectable disease after treatment in breast cancer

P6-10-11: In vitro chemo interrogation of viable circulating tumour-associated cells from breast cancer patients

Encyclopaedic tumour analysis-guided treatments with conventional drugs outperform available alternatives in refractory head and neck cancers

Analytical and clinical validation of the EasyCheck360^® platform for diagnostic triaging of symptomatic cases suspected of colorectal cancer

PS2-40: Analytical and clinical validation of the EasyCheck360^® platform for diagnostic triaging of symptomatic cases suspected of breast cancer

P059 Analytical and clinical validation of the EasyCheck360^® platform for diagnostic triaging of symptomatic cases suspected of prostate cancer